Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled mRNA therapy for cystic fibrosis.In the second cohort of the study, six Class I CF adults received inhaled 10 mg doses of ARCT-032 daily over 28 days. The treatment was generally safe and well-tolerated.Treatment-related AEs identified in the single-dose Phase 1 study were also observed in some participants for ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Key Takeaways Wabtec's Q3 EPS of $2.32 beat estimates and rose 16% year over year on higher sales and margin gains.Q3 revenue climbed 8.4% to $2.88B, led by solid Freight and Transit segment performance.Wabtec updated its 2025 adjusted EPS view to $8.85-$9.05 while keeping revenue guidance unchanged.Westinghouse Air Brake Technologies Corporation (WAB) reported encouraging third-quarter 2025 results wherein both earnings and revenues surpassed the Zacks Consensus Estimate as well as reported year-over-year ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX).And retail traders should know.We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VKTX, it often means somebody knows something is about to happen.Today, Benzinga's options scanner spotted 12 options trades for Viking Thera ...

Core Insights - Travel + Leisure Co. (TNL) is a significant player in the leisure travel industry, focusing on vacation ownership and travel services, and has demonstrated strong financial performance [1] Financial Performance - TNL reported third-quarter earnings on October 22, 2025, with revenue of $1.04 billion, exceeding the estimated $995 million and showing an increase from $993 million in the same period last year [2] - The company's earnings per share (EPS) for the third quarter reached $1.80, surpassing the Zacks Consensus Estimate of $1.72, and increased from $1.57 in the same quarter last year, with an earnings surprise of +4.65% [3] - The Vacation Ownership segment generated $876 million in revenue, reflecting a 6% increase compared to the previous year, while TNL's net income for the quarter was $111 million, translating to $1.67 in diluted EPS [4] Investment Profile - TNL's financial metrics indicate a solid investment profile, with a price-to-earnings (P/E) ratio of approximately 11.16 and a price-to-sales ratio of about 1.12, suggesting attractive valuation metrics [5] - The enterprise value to sales ratio is around 1.06, and the enterprise value to operating cash flow ratio is approximately 6.85, indicating strong operational efficiency [5] - TNL's current ratio of 3.03 suggests a strong liquidity position, ensuring the company can meet its short-term obligations [5][6]

About Erie Insurance According to A.M. Best Company, Erie Insurance Group, based in Erie, Pennsylvania, is the 11th largest homeowners insurer, 12th largest automobile insurer and 13th largest commercial lines insurer in the United States based on direct premiums written. Founded in 1925, Erie Insurance is a Fortune 500 company and the 16th largest property/casualty insurer in the United States based on total lines net premium written. Rated A (Excellent) by A.M. Best, ERIE has more than 7 million policies ...

Core Points - Diagnos Inc. intends to extend the exercise period of 1,125,000 stock warrants from November 9, 2025, to August 5, 2026, subject to TSX Venture Exchange consent [1][2] - The exercise price of the warrants will remain unchanged at $0.40 per common share during the extended period [2] Company Overview - Diagnos Inc. is a publicly traded Canadian corporation focused on the early detection of critical eye-related health issues using advanced Artificial Intelligence technology [4] - The company's goal is to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [4]

NEW YORK, NY / ACCESS Newswire / October 22, 2025 / Every investor knows the reflex. You see the words reverse split, and your instincts flinch. ...

Core Points - Diagnos Inc. intends to extend the exercise period of 1,125,000 stock warrants from November 9, 2025, to August 5, 2026, subject to TSX Venture Exchange consent [1][2] - The exercise price of the warrants will remain unchanged at $0.40 per common share during the extended period [2] Company Overview - Diagnos is a publicly traded Canadian corporation focused on the early detection of critical eye-related health issues using Artificial Intelligence [4] - The company's technology aims to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [4]

Share JASPER, Ind.--(BUSINESS WIRE)--Kimball Electronics, Inc. (Nasdaq: KE) today announced that it will report first quarter fiscal year 2026 financial results on Wednesday, November 5, 2025, after the closing of the market. The company will host a conference call and live webcast to review the results on Thursday, November 6, 2025, at 10:00 a.m. Eastern Time. Kimball Electronics Q1 Fiscal 2026 earnings conference call and webcast to be held on Thursday, November 6, at 10:00 a.m. Eastern Time. Kimball Elec ...